ABOUT ADCS

The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego. The ADCS is a major initiative for Alzheimer’s disease (AD) clinical studies in the Federal Government, addressing treatments for both cognitive and behavioral symptoms. The ADCS is part of the NIA Division of Neuroscience’s effort to facilitate the discovery, development and testing of new drugs for the treatment of AD and is part of the Alzheimer’s Disease Prevention Initiative as well.

CURRENT ADCS STUDIES

EXERT Study

EXERT is a national, 18-month clinical trial to test whether physical exercise can slow the progression of early Alzheimer’s disease-related memory problems or mild cognitive impairment in older adults. 15 academic medical centers and YMCA’s in the US are participating in the EXERT study.

DISCOVER Study

The Discover Study is a randomized, double-blind, placebo controlled study. Participants will be treated with a low, middle, or high dose of Posiphen, or a placebo (a capsule that looks like the study drug but does not contain active ingredients).

NOBLE Study

NOBLE is a clinical study to evaluate an investigational drug for patients with mild to moderate Alzheimer’s disease. The investigational drug may work by protecting brain cells, which could result in improved memory. The study will determine whether the drug is efficacious.

3 Star Study

The 3 Star Study will research and test whether an investigational vaccine can affect Alzheimer’s disease-related brain changes in participants with Down Syndrome. The clinical research site is looking for individuals who meet the following criteria: have Down Syndrome, are 35 to 45 years of age, do not have any other serious illness, and have a caregiver/informant who can answer questions about them.

ADCS RESEARCH NEWS

University of South Florida researchers quantify Alzheimer’s and other neuro disease at $800 billion per year and growing. Read ”The US the Burden of Neurological Disease in the United States: Summary Report and Call to Action” published this week in the Annals of Neurology

In this editorial, we provide a summary overview of the substantial current and future economic impact of neurological disease, and provide an action plan for reducing this burden through neurological research and enhanced clinical management of neurological disorders in the United States.

OUR AFFILIATES

NIH
NIH senior
ACTRI
UCSD Health Sciences
Eldercare Locator
Caregiver Media Group
Alzheimer’s Foundation of America
National Respite Network
Bright Focus Foundation
Alzheimer’s disease education & Ref Center
Family Caregiver Alliance
Alzheimer’s Association